Mathematical modelling and data science company Physiomics plc (AIM: PYC) announced on Monday that it has been awarded an additional contract by Numab Therapeutics, an existing client.

The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling to support Numab's oncology asset entering clinical trials, aiding in dose and scheduling decisions.

Dr Peter Sargent, CEO, expressed enthusiasm about the opportunity to support Numab through the preclinical stages into clinical trials. This project, coupled with the one announced in August 2023, reflects the ongoing collaborative relationship and support provided by Physiomics.

Physiomics leverages advanced PKPD and QSP modelling, along with deep biology expertise, to assist biotech and pharma companies in streamlining drug development. The company's data-driven approach aims to de-risk decision making and optimise research design across discovery, pre-clinical, and clinical studies.

With a focus on deriving insights from relevant data, Physiomics has contributed to over 100 commercial projects, 50 targets, and 75 drugs. Notable clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and CRUK.